Inhibrx Biosciences (INBX) Total Debt (2023 - 2026)
Inhibrx Biosciences (INBX) posted quarterly Total Debt of $100.6 million for Q4 2025, up 0.64% quarter-over-quarter from $99.9 million in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Total Debt (2023 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Total Debt for 2 consecutive years, with $100.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Debt changed N/A year-over-year to $100.6 million; the TTM figure through Dec 2025 stood at $100.6 million (changed N/A YoY), while the FY2025 annual figure was $100.6 million, changed N/A from the prior year.
- Total Debt improved to $100.6 million in Q4 2025 per INBX's latest filing, from $99.9 million in the prior quarter.
- Across five years, Total Debt topped out at $207.0 million in Q4 2023 and bottomed at $98.7 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1.07 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 9.34 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | 176.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 176.29 Mn |
| Dec 31, 2025 | 100.56 Mn |
| Sep 30, 2025 | 99.92 Mn |
| Jun 30, 2025 | 99.28 Mn |
| Mar 31, 2025 | 98.65 Mn |
| Dec 31, 2023 | 206.97 Mn |